Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | LMNA | P02545 | 7/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29737158 | 0.92 | NOTUM (0.64) | TP53ALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL1021359 | 0.92 | NOTUM (0.64) | TP53ALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL1908587 | 0.89 | TDP1 (0.58) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL27559350 | 0.86 | TP53 (0.70) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL2289614 | 0.83 | SMN1; SMN2 (0.57) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL2227782 | 0.83 | CA1 (0.65) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL4808175 | 0.81 | NOTUM (0.67) | TP53ALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL1807646 | 0.80 | ALDH1A1 (0.64) | ALDH1A1LMNASMN1; SMN2PKMMEN1 | |
| SCHEMBL21832028 | 0.80 | NOTUM (0.59) | TP53ALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL3127789 | 0.80 | ALDH1A1 (0.55) | TP53ALDH1A1LMNATSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150526-A1 | COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY (US) | 2023-08-10 | — | — | WO | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1243583-B1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | EISAI CO LTD (JP) | 2005-09-28 | — | — | EP | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-6787534-B2 | SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS | EISAI CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | TP53 1347/4885ALDH1A1 1256/4885LMNA 3673/4885 |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | TP53 3890/4885ALDH1A1 215/4885LMNA 2697/4885 |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | TP53 4798/4885ALDH1A1 745/4885LMNA 4307/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | TP53 3890/4885ALDH1A1 215/4885LMNA 2697/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | TP53 1347/4885ALDH1A1 1256/4885LMNA 3673/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | TP53 2373/4885ALDH1A1 1266/4885LMNA 3427/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | TP53 3580/4885ALDH1A1 1018/4885LMNA 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.